Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

The generation of gut microbiome, cross-reactive autoantibodies in fibromyalgia pain

FY 2024-25

Summary
Fibromyalgia (FM) is a chronic pain condition affecting approximately 2% of the population and is characterized by widespread pain and hypersensitivity. Recent findings revealed a role for IgG autoantibodies in FM pain, yet their function remains unknown. FM patients exhibit an altered gut microbiome, raising the possibility that microbial antigens drive autoantibody production through cross-reactivity. Cross-reactivity is a process where immune responses to pathogenic antigens mistakenly target self-antigens. Our preliminary data show FM IgG antibodies have an increased binding to gut bacteria, and FM microbiota transfer induces pain-like behavior in germ-free mice. We hypothesize that FM microbiota promote autoantibody development via cross-reactivity and anticipate that T and B cell inhibition will impact FM microbiota-induced pain. This study will investigate how the FM microbiota promote IgG+ plasma cell proliferation, autoantibody development, and how T and B cells drive pain. Germ-free mice will receive fecal microbiota transplants from FM or control donors. Gut-associated lymphoid tissues and antibody response to bacteria will be assessed with flow cytometry. Development of autoantibodies against glia cells will be assessed with immunofluorescent staining. To determine the roles of T and B cells, we will deplete B cells using anti-CD20 monoclonal antibodies and inhibit T cells with CTLA-4-Ig, followed by behavioral pain assessments. This research could elucidate gut microbiota-neuroimmune interactions in FM and lead to novel therapeutic strategies.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
562335
Name
Roy Ezrah Isaac
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The generation of gut microbiome, cross-reactive autoantibodies in fibromyalgia pain
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoantibodies; B Cells; Fibromyalgia; Gut Microbiome; Immunology; Pain; T Cells
Abstract
Fibromyalgia (FM) is a chronic pain condition affecting approximately 2% of the population and is characterized by widespread pain and hypersensitivity. Recent findings revealed a role for IgG autoantibodies in FM pain, yet their function remains unknown. FM patients exhibit an altered gut microbiome, raising the possibility that microbial antigens drive autoantibody production through cross-reactivity. Cross-reactivity is a process where immune responses to pathogenic antigens mistakenly target self-antigens. Our preliminary data show FM IgG antibodies have an increased binding to gut bacteria, and FM microbiota transfer induces pain-like behavior in germ-free mice. We hypothesize that FM microbiota promote autoantibody development via cross-reactivity and anticipate that T and B cell inhibition will impact FM microbiota-induced pain. This study will investigate how the FM microbiota promote IgG+ plasma cell proliferation, autoantibody development, and how T and B cells drive pain. Germ-free mice will receive fecal microbiota transplants from FM or control donors. Gut-associated lymphoid tissues and antibody response to bacteria will be assessed with flow cytometry. Development of autoantibodies against glia cells will be assessed with immunofluorescent staining. To determine the roles of T and B cells, we will deplete B cells using anti-CD20 monoclonal antibodies and inhibit T cells with CTLA-4-Ig, followed by behavioral pain assessments. This research could elucidate gut microbiota-neuroimmune interactions in FM and lead to novel therapeutic strategies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Roy, Ezrah Isaac
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~